[Use of a combination of cefoperazone with sulbactam for treatment of patients with wound infections].
The clinical efficacy of sulperazone (cefoperazone + sulbactam) manufactured by Pfizer (USA) was studied in the treatment of 25 patients with wound infections. By the disease severity and complications 9 patients belonged to the risk group. Insulators with abacterial media or bandages with ointments on the polyethylene glycol base and drugs stimulating reparative processes (methyl-diadioxylin, dioxyzol, gentacycol) were used for the local treatment of the wounds. The clinical efficacy was stated in 92 per cent of the cases and in 76 per cent of the cases the efficacy was bacteriological. The tolerance of sulperazon was good in all the cases. The signs of the drug intolerance or affection of the hepatic or renal function were not detected. 281 clinical isolates of the aerobic microflora were tested for their antibiotic susceptibility. The highest susceptibility to sulperazone was observed in gram-positive organisms, gram-negative bacilli (Proteus mirabilis, Escherichia coli and Klebsiella spp.) and some nonfermenting bacteria.
Iakovlev
V P
VP
Blatun
L A
LA
Puchkova
L S
LS
Svetukhin
A M
AM
D000293:Adolescent; D000328:Adult; D000368:Aged; D002438:Cefoperazone / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013407:Sulbactam / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy*
D004338:Drug Combinations; D002438:Cefoperazone; C057923:sulperazone; D013407:Sulbactam
Primenenie kombinatsii tsefoperazona s sul'baktamom dlia lecheniia bol'nykh s ranevoĭ infektsieĭ.